Yingqiu Xie_Assistant Professor

Yingqiu Xie, PhD


Department: Biology
Position: Assistant Professor
Degree:
Office: 7e.541
Email: Yingqiu.xie@nu.edu.kz
Phone: +7 (7172) 694686

EDUCATION

2000 –   Postdoc, University of Maryland School of Medicine; Wadsworth Center, New York State Department of Health;

1999 – Ph.D., Chinese Academy of Sciences


Dr. Xie received the Ph.D. in Genetics from Institute of Genetics and Developmental Biology, Chinese

Academy of Sciences. During Ph.D. studies, Dr. Xie discovered a strong promoter for bioengineering from

viral genome which was awarded a USA patent. During his postdoctoral training, Dr. Xie discovered novel

diagnostic and prognostic markers of prostate cancer such as PIM-1L and nMET.  Dr. Xie also found

mechanisms of multiple drug resistance, novel signaling networks in prostate, breast cancer and

leukemia. Dr. Xie has been invited as speaker in a number of international conferences in USA and China.

Dr. Xie has supervised students to carry out cancer research and to publish their research results since he

joined the Nazarbayev University as an Assistant Professor in 2015. Dr. Xie’s current research is focusing

on molecular and biochemical mechanisms of cancer progression and precision cancer therapeutics.


RESEARCH INTERESTS  

Signaling networks and drug target in lung cancer, prostate cancer, breast cancer and leukemia; Cancer

drug resistance and stem cells; Aging in cancer; Environmental health; Clinical urologic oncology.


SELECTED PUBLICATIONS

1. Lu W, Liu S, Li B, Xie Y, MG Izban, BR Ballard, SA Sathyanarayana, SE Adunyah, RJ Matusik and

Chen Z. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress

prostate cancer. Oncogene, 2016, In Press. (http://www.nature.com/onc/index.html )

 

2. Xie Y*, Istayeva S, Chen Z, Tokay T, Zhumadilov Z, Wu D, Hortelano G, Zhang J. nMET, a new

target in recurrent cancer. Current Cancer Drug Targets, 16(7):572-8, 2016. (*Corresponding

author at Nazarbayev University)

 

3. Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz

N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, Carver BS. Identifying actionable

targets through integrative analyses of GEM model and human prostate cancer genomic profiling.

Mol Cancer Ther. 14(1):278-88, 2015.

 

4. Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z. Slug

regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Molecular Oncology, 8(7),

1355-1364, 2014.

 

5. Xie Y, Lu W, Liu S, Yang Q, Carver BS, Li E, Wang Y, Fazli L, Gleave M, Chen Z. Crosstalk

between Nuclear MET and SOX9/β-Catenin Correlates with Castration Resistant Prostate Cancer.

Molecular Endocrinology, 28(10),1629-1639, 2014.

 

6. Linn DE*, Yang X*, Xie Y, Alfano A, Deshmukh D, Wang X, Shimelis H, Chen H, Li W, Xu K, Chen

M, Qiu Y.  Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-

dependent recruitment of distinct ubiquitin E3 ligases. Journal of Biological Chemistry, 287(27),

22959-22968, 2012.  (*co-first authors)

 

7. Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL.

Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic

strategy in breast cancer. Endocrine Related Cancer, 18, 207-211, 2011.

 

8.  Xie Y*, Burcu M*, Linn DE, Qiu Y, Baer MR. Pim-1 kinase protects P-glycoprotein from

degradation and enables its glycosylation and cell surface expression. Molecular Pharmacology,

78(2), 310-318, 2010. (*co-first authors)

 

9.  Xie Y, Xu K, Linn DE, Yang X, Guo Z, Shimelis H, Nakanishi T, Ross DD, Chen H, Fazli L, Gleave

ME, Qiu Y. The 44 kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its

multimerization and drug resistant activity in human prostate cancer cells. Journal of Biological

Chemistry, 283, 3349-3356, 2008. 

 

10. Xie Y, Burcu M, Baer MR. PKC412 directly inhibits the serine/threonine protein kinase PIM-1 in

cell lines and acute myeloid leukemia cells as a novel mechanism of inhibition of multidrug

resistance. Blood, 112 (11), 2655, 2008. (Conference Abstract)

 

11. Xie Y, Xu K, Dai B, Guo Z, Jiang T, Chen H, Qiu Y. The 44 kDa Pim-1 kinase directly interacts with

tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by

chemotherapeutic drugs. Oncogene, 25, 70-78, 2006.

 

12. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar

VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y. Regulation of androgen receptor activity by

tyrosine phosphorylation. Cancer Cell, 10, 309-319, 2006.

 

13. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, Kong X, Melamed J, Chen H, Bieberich CJ, Borowsky

AD, Kung HJ, Wei G, Ostrowski MC, Brodie A, Qiu Y. Tyrosine kinase Etk/BMX is up-regulated in

human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in

mouse. Cancer Research. 66, 8058-8064, 2006.

 

14. Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y. Synergism of cytoplasmic kinases in IL-6- induced

ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene, 23, 1838-

1844, 2004.